目的 系統(tǒng)評價沙利度胺聯(lián)合其他藥品治療類風(fēng)濕關(guān)節(jié)炎的有效性與安全性。方法 檢索2017年9月1日前發(fā)表在PubMed、Medline、Web of Science及中國知網(wǎng)（CNKI）、中國生物醫(yī)學(xué)文獻數(shù)據(jù)庫（CBM）、維普數(shù)據(jù)庫（VIP）、萬方數(shù)據(jù)庫中相關(guān)的隨機對照試驗（RCTs），應(yīng)用State 14.0軟件進行Meta-分析。結(jié)果 共納入15篇相關(guān)文獻，累計1 246例患者。Meta-分析結(jié)果顯示，聯(lián)用沙利度胺組在有效率（OR=2.71，95% CI=1.87~3.93，P<0.05）、關(guān)節(jié)腫脹數(shù)（OR=1.68，95% CI=0.99~2.37，P<0.05）、關(guān)節(jié)壓痛數(shù)（OR=2.22，95% CI=1.31~3.14，P<0.05）、紅細(xì)胞沉降率（OR=12.93，95% CI=10.26~15.60，P<0.05）等方面療效均優(yōu)于對照組。在不良反應(yīng)發(fā)生率方面，聯(lián)用沙利度胺組與對照組比較無顯著性差異（OR=0.93，95% CI=0.66~1.32，P>0.05）。結(jié)論 聯(lián)用沙利度胺在類風(fēng)濕關(guān)節(jié)炎的治療中有積極作用。

Objective To systematically review the efficiency and safety of thalidomide combined with other drugs in the treatment of rheumatoid arthritis. Methods The randomized controlled trials (RCTs) about thalidomide treating rheumatoid arthritis were retrieved in the database of PubMed, Medline Web of science, CNKI, VIP, CBM, and Wanfang Data from the date of database foundation to August 2017. Meta-analysis was performed with state14.0 software. Results A total of 15 RCTs involving 1 246 patients were finally included; Meta-analysis results showed that, the effect of thalidomide combined with control was superior to control alone in the effective rate (OR=2.71, 95% CI=1.87-3.93, P<0.05), joint swelling number (OR=1.68, 95% CI=0.99-2.37, P<0.05), joint tenderness number(OR=2.22, 95% CI=1.31-3.14, P<0.05), and erythrocyte sedimentation rate (OR=12.93, 95% CI=10.26-15.60, P<0.05). There was no significant difference in the occurrence of adverse events between the thalidomide group and control group (OR=0.93, 95% CI=0.66-1.32, P>0.05). Conclusion Thalidomide combined with other drugs has a positive effect on the treatment of rheumatoid arthritis.

遼寧省科學(xué)技術(shù)計劃項目（2014226033）